Long-term outcomes with nonmyeloablative HLA-identical related HCT using tacrolimus and MMF for GVHD prophylaxis

Nonmyeloablative conditioning using low-dose total body irradiation (TBI) with or without fludarabine (FLU) and HLA-matched donor peripheral blood hematopoietic cell transplantation (HCT) is an effective therapy for many hematologic malignancies. Although this approach achieves reliable engraftment with reduced regimen-related toxicity, the major causes of non-relapse mortality (NRM) are the development of acute and chronic graft-versus-host-disease (GVHD).1,2 Historically, cyclosporine (CSP) has been used in combination with mycophenolate mofetil (MMF) for post-grafting immunosuppression in the nonmyeloablative setting due to demonstrated synergy in preventing GVHD and improvement in survival in the canine model.

Source: Biology of Blood and Marrow Transplantation - December 11, 2020 Category: Hematology Authors: Masumi Ueda Oshima, Barry E. Storer, Huiying Qiu, Thomas Chauncey, Julie Asch, Michael W. Boyer, Luisa Giaccone, Mary Flowers, Marco Mielcarek, Rainer Storb, David G Maloney, Brenda M. Sandmaier Source Type: research